Analyst Price Targets — COR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 1:11 pm | — | Evercore ISI | $360.00 | $324.93 | TheFly | Cencora price target lowered to $360 from $420 at Evercore ISI |
| March 17, 2026 2:42 pm | — | Morgan Stanley | $380.00 | $334.15 | StreetInsider | BofA Securities stays Neutral on Cencora Inc (COR) amid guidance reiteration, CFO departure |
| February 13, 2026 11:09 am | — | Barclays | $425.00 | $351.06 | TheFly | Cencora price target raised to $425 from $400 at Barclays |
| February 10, 2026 11:35 am | — | Wells Fargo | $429.00 | $363.27 | TheFly | Cencora price target raised to $429 from $405 at Wells Fargo |
| February 5, 2026 1:21 pm | — | Evercore ISI | $420.00 | $354.83 | TheFly | Cencora price target lowered to $420 from $440 at Evercore ISI |
| January 29, 2026 10:28 am | — | Morgan Stanley | $400.00 | $350.54 | TheFly | Morgan Stanley upgrades Cencora to Overweight on specialty position |
| January 22, 2026 6:02 am | Brian Tanquilut | Jefferies | $440.00 | $351.75 | StreetInsider | Jefferies Upgrades Cencora Inc (COR) to Buy |
| January 13, 2026 1:32 pm | Eric Coldwell | Robert W. Baird | $415.00 | $345.30 | TheFly | Cencora price target raised to $415 from $392 at Baird |
| December 16, 2025 1:38 pm | — | Robert W. Baird | $392.00 | $345.64 | TheFly | Cencora price target lowered to $392 from $395 at Baird |
| December 8, 2025 9:12 pm | — | Barclays | $400.00 | $337.82 | TheFly | Cencora initiated with an Overweight at Barclays |
Latest News for COR
Assetmark Inc. lifted its stake in shares of Cencora, Inc. (NYSE: COR) by 57.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,281 shares of the company's stock after buying an additional 24,431 shares during the quarter. Assetmark Inc.'s holdings in
Massachusetts Financial Services Co. MA lowered its holdings in Cencora, Inc. (NYSE: COR) by 13.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 568,119 shares of the company's stock after selling 89,591 shares during the period. Massachusetts Financial Services Co. MA
Cencora (COR) gets its prior buy rating from 2025 reaffirmed, driven by several strong fundamentals, despite a recent price retreat. The healthcare distributor has a global brand footprint, a key role in serving specific clinical needs, and profitability, despite thin margins. The dividend case is compelling, with proven 10 year growth across many market cycles, and a low payout ratio.
KindlyMD (NASDAQ: NAKA - Get Free Report) and Cencora (NYSE: COR - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation. Profitability This table compares KindlyMD and Cencora's net margins, return
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.